# Zevra Therapeutics, Inc.: financial statements, quarterly

ZVRA · Nasdaq · CIK 1434647 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/zvra.md) · [Financials](/companies/zvra/financials.md) · [Filings](/companies/zvra/filings.md) · [Insiders](/companies/zvra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/zvra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.9](/filings/0001437749-24-034916.md) | [12.9 d](/filings/0001437749-25-007320.md) | [3.4](/filings/0001437749-25-016523.md) | [4.4](/filings/0001628280-25-039967.md) | [3.7](/filings/0001434647-25-000011.md) | [12.0 d](/filings/0001434647-26-000011.md) | [20.4](/filings/0001434647-26-000031.md) | [25.9](/filings/0001434647-26-000068.md) | [26.1](/filings/0001434647-25-000011.md) | [34.1 d](/filings/0001434647-26-000011.md) | [36.2](/filings/0001434647-26-000031.md) | [39.7](/filings/0001434647-26-000068.md) |
| Cost of revenue | $m | [0.1](/filings/0001437749-23-030690.md) | [2.0 d](/filings/0001437749-24-010430.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [5.8](/filings/0001437749-24-034916.md) | [14.7 d](/filings/0001437749-25-007320.md) | [9.9](/filings/0001437749-25-016523.md) | [12.6](/filings/0001628280-25-039967.md) | [16.2](/filings/0001434647-25-000011.md) | [16.1 d](/filings/0001434647-26-000011.md) | [19.5](/filings/0001434647-26-000031.md) | [20.8](/filings/0001434647-26-000068.md) | [16.9](/filings/0001434647-25-000011.md) | [20.4 d](/filings/0001434647-26-000011.md) | [20.8](/filings/0001434647-26-000031.md) | [16.6](/filings/0001434647-26-000068.md) |
| Operating income | $m | [(15.4)](/filings/0001437749-24-034916.md) | [(15.2) d](/filings/0001437749-25-007320.md) | [(20.5)](/filings/0001437749-25-016523.md) | [(23.8)](/filings/0001628280-25-039967.md) | [(27.3)](/filings/0001434647-25-000011.md) | [(15.4) d](/filings/0001434647-26-000011.md) | [(5.4)](/filings/0001434647-26-000031.md) | [(71.0)](/filings/0001434647-26-000068.md) | [4.1](/filings/0001434647-25-000011.md) | [9.3 d](/filings/0001434647-26-000011.md) | [52.1](/filings/0001434647-26-000031.md) | [16.8](/filings/0001434647-26-000068.md) |
| Interest expense | $m | [0.4](/filings/0001437749-23-030690.md) | [0.8 d](/filings/0001437749-24-010430.md) | [0.7](/filings/0001437749-24-015705.md) | [2.1](/filings/0001628280-25-039967.md) | [2.3](/filings/0001434647-25-000011.md) | [2.2 d](/filings/0001434647-26-000011.md) | [2.0](/filings/0001434647-26-000031.md) | [2.0](/filings/0001434647-26-000068.md) | [2.1](/filings/0001434647-25-000011.md) | [1.9 d](/filings/0001434647-26-000011.md) | [1.7](/filings/0001434647-26-000031.md) | [0.0](/filings/0001434647-26-000068.md) |
| Income tax | $m | [0.2](/filings/0001437749-24-034916.md) | [0.0 d](/filings/0001437749-25-007320.md) | [(0.1)](/filings/0001437749-25-016523.md) | [0.1](/filings/0001628280-25-039967.md) | [0.0](/filings/0001434647-25-000011.md) | [15.4 d](/filings/0001434647-26-000011.md) | [1.2](/filings/0001434647-26-000031.md) | [2.2](/filings/0001434647-26-000068.md) | [(0.4)](/filings/0001434647-25-000011.md) | [0.5 d](/filings/0001434647-26-000011.md) | [6.9](/filings/0001434647-26-000031.md) | [4.0](/filings/0001434647-26-000068.md) |
| Net income | $m | [(10.4)](/filings/0001437749-24-034916.md) | [(19.9) d](/filings/0001437749-25-007320.md) | [(16.6)](/filings/0001434647-25-000011.md) | [(19.9)](/filings/0001434647-25-000011.md) | [(33.2)](/filings/0001434647-25-000011.md) | [(35.7) d](/filings/0001434647-26-000011.md) | [(3.1)](/filings/0001434647-26-000068.md) | [74.7](/filings/0001434647-26-000068.md) | [(0.5)](/filings/0001434647-25-000011.md) | [12.2 d](/filings/0001434647-26-000011.md) | [37.9](/filings/0001434647-26-000068.md) | [8.8](/filings/0001434647-26-000068.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | [(0.48)](/filings/0001628280-25-039967.md) | [(0.69)](/filings/0001434647-25-000011.md) | not reported | [(0.06)](/filings/0001434647-26-000031.md) | [1.21](/filings/0001434647-26-000068.md) | [(0.01)](/filings/0001434647-25-000011.md) | not reported | [0.60](/filings/0001434647-26-000031.md) | [0.14](/filings/0001434647-26-000068.md) |
| Basic EPS | $ per share | [(0.30)](/filings/0001437749-24-034916.md) | not reported | [(0.40)](/filings/0001437749-25-016523.md) | [(0.48)](/filings/0001628280-25-039967.md) | [(0.69)](/filings/0001434647-25-000011.md) | not reported | [(0.06)](/filings/0001434647-26-000031.md) | [1.24](/filings/0001434647-26-000068.md) | [(0.01)](/filings/0001434647-25-000011.md) | not reported | [0.62](/filings/0001434647-26-000031.md) | [0.14](/filings/0001434647-26-000068.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [43.3](/filings/0001437749-23-030690.md) | [43.0](/filings/0001437749-25-007320.md) | [42.8](/filings/0001437749-24-015705.md) | [39.3](/filings/0001437749-24-026474.md) | [54.0](/filings/0001437749-24-034916.md) | [33.8](/filings/0001434647-26-000011.md) | [37.3](/filings/0001437749-25-016523.md) | [47.7](/filings/0001628280-25-039967.md) | [54.4](/filings/0001434647-25-000011.md) | [62.4](/filings/0001434647-26-000068.md) | [95.6](/filings/0001434647-26-000031.md) | [145](/filings/0001434647-26-000068.md) |
| Current assets | $m | [137](/filings/0001437749-23-030690.md) | [86.9](/filings/0001437749-25-007320.md) | [62.9](/filings/0001437749-24-015705.md) | [60.9](/filings/0001437749-24-026474.md) | [99.4](/filings/0001437749-24-034916.md) | [86.0](/filings/0001434647-26-000011.md) | [81.6](/filings/0001437749-25-016523.md) | [226](/filings/0001628280-25-039967.md) | [225](/filings/0001434647-25-000011.md) | [223](/filings/0001434647-26-000068.md) | [230](/filings/0001434647-26-000031.md) | [251](/filings/0001434647-26-000068.md) |
| Total assets | $m | [139](/filings/0001437749-23-030690.md) | [172](/filings/0001437749-25-007320.md) | [151](/filings/0001437749-24-015705.md) | [144](/filings/0001437749-24-026474.md) | [192](/filings/0001437749-24-034916.md) | [178](/filings/0001434647-26-000011.md) | [173](/filings/0001437749-25-016523.md) | [256](/filings/0001628280-25-039967.md) | [270](/filings/0001434647-25-000011.md) | [285](/filings/0001434647-26-000068.md) | [279](/filings/0001434647-26-000031.md) | [303](/filings/0001434647-26-000068.md) |
| Current liabilities | $m | [21.7](/filings/0001437749-23-030690.md) | [73.7](/filings/0001437749-25-007320.md) | [29.9](/filings/0001437749-24-015705.md) | [30.4](/filings/0001437749-24-026474.md) | [34.5](/filings/0001437749-24-034916.md) | [34.1](/filings/0001434647-26-000011.md) | [27.0](/filings/0001437749-25-016523.md) | [28.8](/filings/0001628280-25-039967.md) | [26.1](/filings/0001434647-25-000011.md) | [39.3](/filings/0001434647-26-000068.md) | [47.0](/filings/0001434647-26-000031.md) | [48.6](/filings/0001434647-26-000068.md) |
| Total liabilities | $m | [71.5](/filings/0001437749-23-030690.md) | [110](/filings/0001437749-25-007320.md) | [102](/filings/0001437749-24-015705.md) | [112](/filings/0001437749-24-026474.md) | [122](/filings/0001437749-24-034916.md) | [138](/filings/0001434647-26-000011.md) | [132](/filings/0001437749-25-016523.md) | [139](/filings/0001628280-25-039967.md) | [137](/filings/0001434647-25-000011.md) | [130](/filings/0001434647-26-000068.md) | [72.8](/filings/0001434647-26-000031.md) | [85.1](/filings/0001434647-26-000068.md) |
| Long-term debt | $m | not reported | [5.1](/filings/0001437749-25-007320.md) | not reported | [58.3](/filings/0001437749-24-026474.md) | [58.9](/filings/0001437749-24-034916.md) | [59.5](/filings/0001434647-26-000011.md) | [60.1](/filings/0001437749-25-016523.md) | [60.7](/filings/0001628280-25-039967.md) | [61.3](/filings/0001434647-25-000011.md) | [61.9](/filings/0001434647-26-000068.md) | [0.0](/filings/0001434647-26-000031.md) | [0.0](/filings/0001434647-26-000068.md) |
| Shareholders' equity | $m | [61.5](/filings/0001437749-24-034916.md) | [61.9](/filings/0001434647-26-000011.md) | [48.8](/filings/0001434647-25-000011.md) | [32.5](/filings/0001434647-25-000011.md) | [69.8](/filings/0001434647-25-000011.md) | [39.7](/filings/0001434647-26-000068.md) | [41.0](/filings/0001434647-26-000068.md) | [117](/filings/0001434647-26-000068.md) | [133](/filings/0001434647-25-000011.md) | [155](/filings/0001434647-26-000068.md) | [206](/filings/0001434647-26-000068.md) | [218](/filings/0001434647-26-000068.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.6) d](/filings/0001437749-24-034916.md) | [(16.2) d](/filings/0001437749-25-007320.md) | [(16.2)](/filings/0001437749-25-016523.md) | [(19.1) d](/filings/0001628280-25-039967.md) | [(18.1) d](/filings/0001434647-25-000011.md) | [(16.3) d](/filings/0001434647-26-000011.md) | [(8.2)](/filings/0001434647-26-000031.md) | [(3.6) d](/filings/0001434647-26-000068.md) | [4.7 d](/filings/0001434647-25-000011.md) | [5.5 d](/filings/0001434647-26-000011.md) | [6.1](/filings/0001434647-26-000031.md) | [17.0 d](/filings/0001434647-26-000068.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001437749-24-034916.md) | [0.1 d](/filings/0001437749-25-007320.md) | [0.0](/filings/0001437749-25-016523.md) | [0.0 d](/filings/0001628280-25-039967.md) | [0.0 d](/filings/0001434647-25-000011.md) | [0.0 d](/filings/0001434647-26-000011.md) | [0.1](/filings/0001434647-26-000031.md) | [0.2 d](/filings/0001434647-26-000068.md) | [0.6 d](/filings/0001434647-25-000011.md) | [(0.0) d](/filings/0001434647-26-000011.md) | [0.0](/filings/0001434647-26-000031.md) | [0.2 d](/filings/0001434647-26-000068.md) |
| Share repurchases | $m | [0.0 d](/filings/0001437749-24-034916.md) | [0.0 d](/filings/0001437749-25-007320.md) | [0.0](/filings/0001437749-24-015705.md) | [0.0 d](/filings/0001437749-24-026474.md) | [0.0 d](/filings/0001437749-24-034916.md) | [0.0 d](/filings/0001437749-25-007320.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2019 (2019-09-30) | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [31.7](/filings/0001437749-20-022028.md) | [3.9](/filings/0001437749-21-019912.md) | [4.4](/filings/0001437749-21-026201.md) | [29.2](/filings/0001437749-21-019912.md) | [35.2](/filings/0001437749-21-026201.md) | [41.9](/filings/0001628280-25-039967.md) | [47.8](/filings/0001434647-25-000011.md) | [54.1](/filings/0001434647-26-000031.md) | [56.3](/filings/0001434647-26-000068.md) | [56.0](/filings/0001434647-25-000011.md) | [60.2](/filings/0001434647-26-000031.md) | [61.3](/filings/0001434647-26-000068.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 59,383,781 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001434647-26-000068.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.